-
Nov 29, 2024 | 
rheumnow.com | Janet Pope
The issues surrounding publication bias are real.
-
Nov 17, 2024 | 
rheumnow.com | Janet Pope
The ACR Convergence meeting in Washington (#ACR24) will showcase nearly 3000 abstracts. With the expanding use of JAK inhibitors, there will be some interesting presentations for off label use. There have been some uncontrolled data that tofacitinib reduced inflammatory myositis disease activity and improved calcinosis in patients with refractory myositis (1). Abstract 1731 is a small RCT of baricitinib in inflammatory myositis comparing early start baricitinib to later start (2).
-
Nov 17, 2024 | 
rheumnow.com | Janet Pope
This year at #ACR24, emulation trials are being presented. Are these ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)? In the latter, both known and unknown confounders should be distributed equally, whereas most observational data has unknown or missing data on factors that are associated with both the intervention and the outcome of interest. What are the strengths of emulation trials?
-
Jul 29, 2024 | 
healio.com | Justin Cooper |Shenaz Bagha |Janet Pope
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
-
Jun 24, 2024 | 
rheumnow.com | Janet Pope
There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA. Data are pending for phase 3 RCTs in SLE, with upadacitinib (30 mg/d) and deucravactinib (6mg bid) after positive phase 2 data. And the list goes on!A giant cell arteritis (GCA) late breaking abstract (LBA0001, EULAR 2024, Vienna) showed steroid sparing and efficacy of upadacitinib in this disease with data that seems very similar (to me) to tociluzimab in GCA.
-
Mar 1, 2024 | 
rmdopen.bmj.com | Peter Taylor |Arthur Kavanaugh |Peter Nash |Janet Pope
Impact of filgotinib on pain control in the phase 3 FINCH studies Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
Dec 6, 2023 | 
rheumnow.com | Janet Pope
Several abstracts have studied the mechanism of action of JAK inhibitors (JAKi) in various diseases. JAKi alter many other mediators affected by the JAK STAT pathway. For instance, T cell signature in blood that is proliferative was associated with a response in RA. The problem is that we don’t know if this signature is unique to JAKi response, or to any treatment in RA (abstract 0013). What to use after failure of csDMARDs in RA?
-
Nov 28, 2023 | 
rheumnow.com | Janet Pope
Here's what I learned at ACR23 that will change the way I practice in rheumatoid arthritis. Which is better in active RA after failure of csDMARDs, a TNFi or a JAKi? Baricitinib was compared to Adalimumab in a pragmatic trial (Abstract 0450). There were approximately 100 patients per arm. Although Baricitinib 4mg daily may have had some slightly deeper responses, the two were not different (statistically non inferiority was met).
-
Nov 20, 2023 | 
rheumnow.com | Janet Pope
You can see that the JAKi/TYK2i have both approved or potential seropositive and seronegative indications. There are also improvements in PsO for the class and studies in CTDs. So, it is difficult to know which to choose. But it gets even harder as there were several new molecules that could be coming. For instance, there is LNK01001, a JAK1i in RA, with results aligned with other JAKi (abstract #L09). TAK-279 is a TYK2i for PsA (abstract #L12).
-
Nov 12, 2023 | 
rheumnow.com | Janet Pope
Several abstracts have studied the mechanism of action of JAK inhibitors (JAKi) in various diseases. JAKi alter many other mediators affected by the JAK STAT pathway. For instance, T cell signature in blood that is proliferative was associated with a response in RA. The problem is that we don’t know if this signature is unique to JAKi response, or to any treatment in RA (abstract 0013). What to use after failure of csDMARDs in RA?
